[ORGANIZATION]
REMODEL-1
Featured in 1 tracked story · first seen
Situations
Novartis remibrutinib Phase III clinical trial results
2 clusters · 14 sources · last updated
Latest: Novartis reports positive Phase III results for oral MS drug remibrutinib
Novartis has reported positive topline results from two Phase III clinical trials, REMODEL-1 and REMODEL-2, evaluating its experimental oral drug remibrutinib for the treatment of relapsing multiple sclerosis. The drug,